POS0667 KNOWN AND LESS KNOWN COMORBIDITIES IN AXIAL SPONDYLOARTHRITIS – WHAT ARE WE OVERLOOKING? RESULTS FROM THE SPARTAKUS COHORT

Background It is well-established that axial spondyloarthritis (axSpA) associated with extra-musculoskeletal manifestations such as anterior uveitis, psoriasis, and inflammatory bowel disease (IBD). Although relevant data exists also regarding other specific comorbid diseases, less reported on the overall comorbidity burden in relation to background population. Objectives To assess frequency of a wide range comorbidities, covering most important organ-domains conditions, population-based axSpA cohort, including both non-radiographic (nr-axSpA) radiographic (r-axSpA) disease, compare this frequencies among matched general population comparator-subjects. Methods We included 246 well-characterised patients (mean age 52 years; 55% male) established from SPARTAKUS comprising defined area southern Sweden. All had undergone thorough clinical assessment were classified nr-axSpA (fulfilling ASAS criteria; n=82) or r-axSpA (meeting modified New York/ASAS n=164). Furthermore, for each patient, 5 comparator-subjects population, sex, age, residence area, randomly drawn Swedish Population Register (n=1230). The 55 different organ-domains, then investigated through ICD-10 diagnostic codes retrieved Skåne Healthcare (covering primary specialised care) collected during 10-year period preceding inclusion cohort (for index cases; same their respective comparator-subjects). Univariate logistic regression was used various comorbidities between comparator-subjects, while employing Benjamini-Hochberg procedure account multiple tests. Comorbidities <5 events either group excluded analysis (n=12). Results Characteristics are displayed Table 1 . Numerically, almost all more frequent than ( Figure ). showed significantly higher known manifestations: uveitis (28% vs. 1% p<0.001), IBD (10% 1%, psoriasis 3%, p<0.001). Also, previously conditions degenerative disc (17% 6%, fibromyalgia (12% p<0.001) nephrolithiasis (8% clearly overrepresented. In addition, proportions well-known side-effects NSAIDs: gastritis (21% vs.10%, hypertension (31% 19%, p<0.001); well glucocorticoids (GC): cataract (11% 7%, p=0.010), glaucoma (7% p=0.008) vertebral compression (4% p=0.002); been hospitalised infections 5%, p=0.006). Conclusion When assessing contemporary have markedly morbidity an expected overrepresentation manifestations, but explored nephrolithiasis, warrant attention proper management. oral GCs generally not recommended axSpA, our results underscore medications common diagnosis, treatments need be closely monitored. AxSpA n=246 Male sex Age, years (13) Symptom duration, 26 (14) Nr-axSpA 33% HLA-B27 positive 86% BMI, kg/m 2 27 (5) Smoking, ever 39% ASDAS-CRP 1.8 (0.9) BASFI 2.1 (2.2) CRP, mg/L 3.8 (7.2) 3-month NSAID score 32 (41) Ongoing csDMARD therapy 20% b/tsDMARD 44% Mean (SD) if otherwise stated. Missing ranging 0-5%. REFERENCES: NIL. Acknowledgements: Disclosure Interests Jonas Sagard: None declared, Elisabeth Mogard Speakers bureau: AbbVie, Novartis, Elisabet Lindqvist: Anna Jöud: Mats Geijer UCB, Johan K Wallman Amgen, Grant/research support from: Eli Lilly, Pfizer, Tor Olofsson Consultant of: MSD.